COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Daily Tenofovir DF to Prevent HIV Infection Among Sex Workers in Cambodia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00078182
Recruitment Status : Withdrawn
First Posted : February 20, 2004
Last Update Posted : December 14, 2016
NCHADS - Ministry of Health of Cambodia
Kirby Institute
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)

Brief Summary:
Tenofovir disoproxil fumarate (also known as tenofovir DF or Viread) is used with other anti-HIV drugs to treat HIV infection. Taking tenofovir DF every day may also prevent HIV infection. This study will determine if taking a tenofovir DF tablet every day is safe and effective in preventing HIV infection. Participants in the study will be sex workers in Phnom Penh, Cambodia.

Condition or disease Intervention/treatment Phase
HIV Infections HIV Seronegativity Drug: Tenofovir DF Phase 2 Phase 3

Detailed Description:

Cambodia has one of the highest rates of HIV infection in Southeast Asia. At the end of 2002, HIV infection rates among Cambodian sex workers ranged from 14.8% to 28.8%. Tenofovir DF is a nucleotide reverse transcriptase inhibitor (NRTI) that was licensed for the treatment of HIV-1 infection by the United States Food and Drug Administration (FDA) in October 2001. This randomized clinical trial will determine if a daily oral 300 mg dose of tenofovir DF is safe and effective in preventing HIV-1 infection. This is a collaborative study between the University of California, San Francisco, the University of New South Wales, and the Ministry of Health of Cambodia.

Nine hundred and sixty HIV uninfected female sex workers in Phnom Penh will be enrolled in the trial. Participants will be randomized to receive either 300 mg of tenofovir DF or placebo daily for 12 months. Participants will be evaluated for rates of HIV infection, adherence to the drug regimen, and changes in risk behaviors. All participants will be monitored throughout the trial for side effects and toxicity. Participants will be involved in the study for 14 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Study of Daily Oral Tenofovir (Tenofovir Disoproxil Fumarate) to Prevent HIV-1 Infection Among Sex Workers in Cambodia

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

  • HIV uninfected
  • Report receiving money or gifts for vaginal or anal sexual intercourse in the year prior to study entry
  • Able to provide a street address of residence for themselves and two personal contacts who would know their whereabouts during the study period
  • Normal lab values within 14 days of study entry
  • Ability to understand spoken Khmer
  • Willing and able to provide written informed consent

Exclusion Criteria

  • Pregnant or breast-feeding
  • Previously diagnosed active or serious infections
  • Certain medications
  • Active alcohol or drug abuse that could interfer with the study
  • Previously diagnosed malignancies other than basal cell carcinoma
  • Any other condition that, in the opinion of the study officials, would preclude informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00078182

Layout table for location information
Phnom Penh, Cambodia
Sponsors and Collaborators
National Institute of Allergy and Infectious Diseases (NIAID)
NCHADS - Ministry of Health of Cambodia
Kirby Institute
Layout table for investigator information
Principal Investigator: Kimberly Shafer, MD
Layout table for additonal information Identifier: NCT00078182    
Other Study ID Numbers: 1U01AI054241-01 ( U.S. NIH Grant/Contract )
First Posted: February 20, 2004    Key Record Dates
Last Update Posted: December 14, 2016
Last Verified: May 2005
Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
HIV Prevention
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Antiviral Agents
Anti-Infective Agents
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Anti-HIV Agents